

Mérieux Equity Partners (Growth & Buyout) invests in Janvier Labs, European leader in translational research products & services

Paris, France – July 19th, 2022 – Mérieux Equity Partners (Growth & Buyout) is pleased to announce that Mérieux Participations 4 fund (MP4) signed a definitive agreement to acquire an interest in Janvier Labs

Founded in 1960 by Roger Janvier and headquartered nearby Laval (France), Janvier Labs is the European leader in translational research products & services. The company offers most innovative rodent research models and services to academia, Pharma, biotech and CRO companies especially in immunology, oncology, infectious diseases, cardiology and metabolism spaces. Through its integrated offering, Janvier Labs aims at empowering clinical research to bring innovative treatments to patients, while complying with highest level of operational excellence and execution.

Mérieux Equity Partners, Janvier Labs management, Unexo and family shareholders share the ambition to create a Global leader in translational research integrating both innovative value-added research models and associated services through organic and targeted external growth initiatives. Following the operation, Merieux Equity Partners will become the Lead Financial investor of the Group, while Janvier Family remains the majority owner of the group.

Thomas Janvier, Janvier Labs CEO said: *“It is a great honor to welcome Mérieux Equity Partners. We believe, that, for Janvier Labs, it is a fantastic opportunity to collaborate with Mérieux Equity Partners and benefit from its ecosystem and network. The value, the knowledge and the ambition of Mérieux Equity Partners made it a perfect partner to develop the activity of the group organically and through targeted M&A.”*

Jean-François Billet, Managing Partner at Mérieux Equity Partners commented: *“We are grateful that Janvier Labs has placed its trust in Mérieux Equity Partners and we look forward to bringing our healthcare expertise and strong international ecosystem to accelerate the development of the Company. We are delighted to partner with Eliane Janvier, Thomas Janvier, Daniel Jaouen and the entire team at Janvier Labs”*

Elias Belkadi, Director at Mérieux Equity Partners said: *“We are impressed by Janvier Labs development history and clear strategy to become a global leader in translational research by combing innovative research models offering to associated services.”*

The investment in Janvier Labs represents the fifth transaction made by Mérieux Participations 4 fund (MP4) – launched in May 2021. MP4 is Mérieux Equity Partners’ latest Growth & Buy-Out investment vehicle, targeting size of €500m, with a hard-cap at €600m. Thanks to this deployment, MP4 is now considered by investors as a “Late Primary opportunity”. The fundraising period of MP4 will end in November 2022.

About Janvier Labs

Janvier Labs is one of the world’s leading players in translational research services. The Company offers innovative rodent research models for biomedical research as well as related services. Based near Laval and founded in 1960, Janvier Labs employs over 350 employees.

About Mérieux Equity Partners

Mérieux Equity Partners ("MxEP") is an AMF-accredited management company dedicated to equity investments in the health and nutrition sector. MxEP actively supports entrepreneurs and companies with differentiated products and services, giving them privileged access to its sector expertise and international network.

For further information about MxEP, please visit: www.merieux-partners.com

Press contacts

Jean-François Billet, Managing Partner – jean-francois.billet@merieux-partners.com

Elias Belkadi, Director – elias.belkadi@merieux-partners.com

List of participants

- **Janvier Labs:** Eliane Janvier, Thomas Janvier, Daniel Jaouen
- **Mérieux Equity Partners:** Jean-François Billet, Elias Belkadi, Pierre-Adrien Ausset, Théophile Sportich

Buy-side

- *Financial Advisor:* **Lazard** (Julien Lestrade, Frederik Rothenburger, Julien Fauconnier, Alice Boutant, Mathilde Errera)
- *Legal Advisor:* **DLA Piper** (Sarmad Haidar, Fanny Combourieu, Sara Gwiazda, Louis-Augustin Jourdan)
- *Commercial Due Diligence:* **Larka** (Pierre-Anthony Brioir, Adrien Chalmont)
- *Financial Due Diligence :* **PwC** (Benoit Cambournac, Benjamin Tixier)
- *Legal Due Diligence :* **PwC** (Eric Hickel, Hélène Struve, Jean François Laigneau)
- *ESG Due Diligence :* **PwC** (François Thueux, Lucas Moscheni, Abia El Filali)
- *Labor and Tax Due Diligences:* **PwC** (Aurélien Cluzel-d'Andlau, Jean-Philippe Brillet, Sophie Desvallées, Joséphine Gosset, Ines Rivoallan, Mathieu Echallier)

Sell-side

- *Financial Advisor:* **Rothschild** (Elena Colucelli, Romain Golven, Benjamin Gorge)
- *Legal Advisor:* **EY** (Philippe Vailhen, Maxime Galinant, Charles Collet)
- *Financial Due Diligence:* **EY** (Marc-André Audisio, Arnaud Guillou)